IRIS
FABBIANI, MASSIMILIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.689
EU - Europa 7.781
AS - Asia 4.848
SA - Sud America 1.127
AF - Africa 142
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 9
Totale 22.605
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.518
RU - Federazione Russa 2.204
IT - Italia 1.952
SG - Singapore 1.532
CN - Cina 1.391
BR - Brasile 971
GB - Regno Unito 875
IE - Irlanda 786
HK - Hong Kong 647
DE - Germania 477
KR - Corea 395
VN - Vietnam 322
SE - Svezia 299
FI - Finlandia 264
FR - Francia 264
UA - Ucraina 219
IN - India 170
NL - Olanda 134
CA - Canada 77
ES - Italia 69
MX - Messico 66
AR - Argentina 63
BD - Bangladesh 54
PL - Polonia 51
CI - Costa d'Avorio 43
ZA - Sudafrica 43
AT - Austria 37
TR - Turchia 37
IQ - Iraq 36
IR - Iran 31
CZ - Repubblica Ceca 30
ID - Indonesia 29
EC - Ecuador 26
JP - Giappone 25
BE - Belgio 21
SA - Arabia Saudita 19
UZ - Uzbekistan 19
AE - Emirati Arabi Uniti 18
PK - Pakistan 16
EG - Egitto 15
LT - Lituania 15
KE - Kenya 14
PY - Paraguay 14
CO - Colombia 13
CH - Svizzera 11
JO - Giordania 11
BG - Bulgaria 10
MA - Marocco 10
MY - Malesia 10
PE - Perù 10
VE - Venezuela 10
CL - Cile 9
IL - Israele 9
AL - Albania 8
LV - Lettonia 8
PH - Filippine 8
PT - Portogallo 8
AU - Australia 7
DO - Repubblica Dominicana 7
EE - Estonia 7
EU - Europa 7
AZ - Azerbaigian 6
BO - Bolivia 6
DK - Danimarca 6
TW - Taiwan 6
BH - Bahrain 5
KZ - Kazakistan 5
RO - Romania 5
TH - Thailandia 5
TN - Tunisia 5
CY - Cipro 4
GE - Georgia 4
GR - Grecia 4
JM - Giamaica 4
KG - Kirghizistan 4
MK - Macedonia 4
OM - Oman 4
UY - Uruguay 4
AM - Armenia 3
BY - Bielorussia 3
CR - Costa Rica 3
HR - Croazia 3
LB - Libano 3
LK - Sri Lanka 3
NG - Nigeria 3
NP - Nepal 3
PA - Panama 3
PS - Palestinian Territory 3
SV - El Salvador 3
DZ - Algeria 2
GH - Ghana 2
GT - Guatemala 2
KH - Cambogia 2
LU - Lussemburgo 2
MD - Moldavia 2
NI - Nicaragua 2
QA - Qatar 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
Totale 22.587
Salva come PNG Salva come JPEG
Città #
Dallas 3.227
Singapore 981
Dublin 772
Southend 700
Moscow 695
Hong Kong 644
Ashburn 570
Hefei 471
Santa Clara 458
Fairfield 438
Chandler 394
Seoul 392
Milan 375
Siena 299
Beijing 279
Munich 246
Woodbridge 241
Houston 205
Seattle 195
Wilmington 171
Los Angeles 168
Jacksonville 165
Helsinki 163
Cambridge 158
Florence 146
Rome 135
Ann Arbor 129
New York 123
Princeton 110
Ho Chi Minh City 109
São Paulo 89
Bengaluru 85
Chicago 67
Buffalo 66
Nuremberg 61
Nanjing 53
Hanoi 50
Boardman 47
Turku 44
Abidjan 43
Redondo Beach 43
Brescia 42
Lauterbourg 42
The Dalles 42
Menlo Park 40
Dong Ket 39
Shanghai 37
Warsaw 36
Düsseldorf 34
San Diego 34
London 33
Málaga 31
Rio de Janeiro 31
Lappeenranta 30
Johannesburg 29
Mexico City 27
Brooklyn 26
Montreal 26
Portsmouth 26
Denver 24
Stockholm 24
Council Bluffs 23
Atlanta 22
Tokyo 22
Brasília 21
Brussels 21
Frankfurt am Main 21
Shenyang 21
Toronto 21
Columbus 19
Fremont 19
Nanchang 19
Guangzhou 18
Phoenix 18
Vienna 18
Chennai 17
Tashkent 17
Washington 17
Curitiba 16
San Mateo 16
Bologna 15
Boston 15
Brno 15
Naples 15
Ribeirão Preto 15
San Francisco 15
Belo Horizonte 14
Amsterdam 13
Orem 13
Paris 13
Poplar 13
Salt Lake City 13
Ankara 12
Changsha 12
Hyderabad 12
Jinan 12
Porto Alegre 12
Aachen 11
Cairo 11
Campinas 11
Totale 15.088
Salva come PNG Salva come JPEG
Nome #
Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study 604
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 543
A first update on mapping the human genetic architecture of COVID-19 537
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 459
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 454
Genetic mechanisms of critical illness in COVID-19 331
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 328
An explainable model of host genetic interactions linked to COVID-19 severity 324
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients 323
Peripheral biomarkers' panel for severe COVID-19 patients 290
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 287
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 286
Colonizzazione e trapianto di polmone: il possibile ruolo dei colonizzanti multiresistenti sugli eventi infettivi in uno studio pilota osservazionale-retrospettivo 282
Pathogen-sugar interactions revealed by universal saturation transfer analysis 269
Mapping the human genetic architecture of COVID-19 260
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 256
Programma di vaccinazione antiMpox e screening infettivologico: opportunità di prevenzione in differenti categorie a rischio 256
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 255
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 254
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 247
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 245
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 240
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 237
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 232
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 213
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 204
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 196
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 194
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 193
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 192
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 191
B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy 184
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 182
WES profiling of COVID-19 182
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 171
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 170
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 170
Epidemiological and clinical study of viral respiratory tract infections in children from Italy 169
Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine 169
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 166
Clinical and molecular characterization of COVID-19 hospitalized patients 166
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 165
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 165
Impact of hepatitis B vaccination in children born to HBsAg-positive mothers: a 20-year retrospective study 163
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine In HIV-Infected Adults 161
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 161
Staphylococcus aureus: studio clinico e microbiologico 161
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 160
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 157
Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection 157
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 156
Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses 156
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 156
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 155
Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study 155
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 153
Colonizzazione da batteri multiresistenti nel trapianto di polmone ed eventi infettivi: studio pilota osservazionale-retrospettivo 151
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound? 148
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 148
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine 146
Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in virological outcomes over time 144
Whole-genome sequencing reveals host factors underlying critical COVID-19 143
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 142
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 138
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe 138
Durability and liver safety of INSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort 138
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: Results from a European multi-cohort study 137
B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response 136
Retrospective study of tuberculosis in the Province of Siena [Studio retrospettivo sui ricoveri per tubercolosi nella provincia di Siena] 135
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine 131
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients. 131
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 131
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 131
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 131
Patient profile characteristics when choosing different Dolutegravir-based dual therapies: impact on long term efficacy and durability 130
Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features 126
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 125
Human bocavirus detection in an atopic child affected by pneumonia associated with wheezing 122
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants 122
Urinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: epidemiology, clinical features and outcomes in the era of antimicrobial resistance 121
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 121
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 121
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 120
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 119
Evolution of anal HPV infection and HPV-related squamous intraepithelial lesions in a cohort of PLWH: is there a benefit of HPV vaccination? 118
Incidenza e fattori di rischio per colonizzazione ed infezione respiratoria batterica a 30 giorni in pazienti trapiantati di polmone 116
Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 monoinfected virologically suppressed patient 115
null 114
Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients 114
PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests” 113
High prevalence of Hepatic Steatosis in a cohort of People Living With HIV: exploring the role of metabolic and HIV-related factors 113
THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN VIROLOGICALLY SUPPRESSED PEOPLE LIVING WITH HIV ON NEUROPSYCHIATRIC SYMPTOMS: PRELIMINARY FINDINGS FROM A RANDOMIZED STUDY 113
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant 110
Vaccinazione anti SARSCov2 in una coorte di pazienti sottoposti a trapianto di cuore o di polmone: risposta umorale a dosi booster 109
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses 109
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 105
A challenging case of SARS-CoV-2- AIDS and Nocardiosis coinfection from the SMatteo COvid19 REgistry (SMACORE) 103
Antimicrobial stewardship: from bedside to theory. Thirteen examples of old and more recent strategies from everyday clinical practice 101
Third Sars-CoV-2 vaccine dose: B cell and antibody responses following heterologous and homologous vaccination strategies. 101
Trattamento efficace di osteomielite sternale con raccolta purulenta da Klebsiella pneumoniae multiresistente in recente trapianto di polmone 99
Totale 18.771
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.337
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.337
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021636 0 0 0 0 0 85 37 116 95 89 102 112
2021/20221.118 107 100 43 59 67 54 56 59 87 86 151 249
2022/20231.669 101 153 173 201 135 309 115 158 142 59 74 49
2023/20241.504 72 45 167 93 72 344 436 67 15 44 56 93
2024/20256.115 171 175 388 238 895 367 564 364 450 306 536 1.661
2025/20269.994 1.015 2.289 2.618 1.781 2.228 63 0 0 0 0 0 0
Totale 23.386